A Randomized, Phase III Study of Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab Investigating EGFR FISH in Patients with Advanced Non-Small Cell Lung Cancer: SWOG S0819

BACKGROUND: EGFR antibodies have been shown to increase survival in patients with advanced non-small cell lung cancer (NSCLC), particularly with squamous cell (SC) histology. Our prior work suggested that EGFR copy number by fluorescence in-situ hybridization (FISH) identifies patients most likely t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet Oncol
Glavni autori: Herbst, Roy S., Redman, Mary W., Kim, Edward S., Semrad, Thomas J., Bazhenova, Lyudmila, Masters, Gregory, Oettel, Kurt, Guaglianone, Perry, Reynolds, Christopher, Karnad, Anand, Arnold, Susanne M., Varella-Garcia, Marileila, Moon, James, Mack, Philip C., Blanke, Charles D., Hirsch, Fred R., Kelly, Karen, Gandara, David R.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847342/
https://ncbi.nlm.nih.gov/pubmed/29169877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30694-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items